2018 annual financial data
Inhibikase Therapeutics 2018 Operating margin
Inhibikase Therapeutics 2018 operating margin with verified reported values.
Direct answer
Operating margin was -52.52%.
Operating income was -2,122,121 USD and net income was -2,152,453 USD.
Operating cash flow was 714,987 USD.
Get free Inhibikase Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 4,040,955 USD
- Operating income
- -2,122,121 USD
- Net income
- -2,152,453 USD
- Operating cash flow
- 714,987 USD